Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2021-02-09 Share Issue/Capital Cha…
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Orient EuroPharma (OEP) entre au capital de Quantum Genomics
Share Issue/Capital Change Classification · 99% confidence The document announces that Orient EuroPharma (OEP) has acquired a minority stake in Quantum Genomics through a reserved capital increase. This involves the issuance of new shares and details the terms (price, lock-up period, settlement date). This activity directly relates to changes in the company's capital structure and fundraising/investment activities. Therefore, it fits the definition of 'Capital/Financing Update' (CAP). It is not a general earnings release (ER), a full annual report (10-K), or a simple announcement of a report (RPA).
2021-02-09 French
Quantum Genomics Launches Phase III Pivotal REFRESH Study in Difficult-to-treat/Resistant Hypertension with Once-a-day Formulation of Firibastat
Regulatory Filings Classification · 94% confidence The document announces the launch of a Phase III clinical study (REFRESH) for a drug (firibastat) targeting resistant hypertension. It details the study design, endpoints, patient enrollment goals, expected timelines for results (mid-2023), and regulatory submissions (NDA). This content relates to ongoing clinical development and future regulatory steps, which is a key aspect of investor relations and corporate updates, but it is not a formal financial report (10-K, IR, ER, MRQ) or a specific legal/governance filing. Since it discusses a major development milestone and future regulatory filings (NDA), it fits best under general corporate/investor news. Given the options, it is a significant corporate announcement that doesn't fit the specific financial report codes. It is not a Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP). It is most closely related to general corporate progress updates. Since it is a detailed announcement about a clinical trial launch and future regulatory plans, it is a significant corporate update. It is not a proxy statement (PSI), remuneration report (DEF 14A), or a formal legal report (LTR). As a major operational/development update, it is best classified as a general Regulatory Filing (RNS) as a catch-all for significant, non-standard announcements, or potentially an Investor Presentation (IP) if it were a slide deck, but here it reads like a press release. Given the nature of announcing clinical trial progress and regulatory timelines, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for significant operational news that isn't a standard financial report.
2021-01-18 English
Lancement de l'Essai REFRESH, Étude Pivotale de Phase III dans l'Hypertension Artérielle Difficile à Traiter/Résistante avec le firibastat en une prise par jour
Regulatory Filings Classification · 95% confidence The document is a press release from a biopharmaceutical company (Quantum Genomics) announcing the launch of a pivotal Phase III clinical trial (REFRESH study) for its drug, firibastat, targeting resistant hypertension. It details the study design, patient recruitment goals, primary endpoints (blood pressure reduction), timeline for results (mid-2023 for 6-month data), and regulatory filing plans (2023). This type of announcement, detailing clinical trial progress, regulatory milestones, and future filing expectations, is characteristic of an announcement related to drug development and regulatory strategy. It is not a formal regulatory filing (like 10-K or IR), nor is it a transcript, earnings release, or management discussion. Since it discusses the progress towards regulatory submission and clinical data, it most closely aligns with general corporate or regulatory updates that don't fit the highly specific categories like M&A (TAR) or Director's Dealing (DIRS). Given the options, this is a significant corporate announcement regarding clinical development and regulatory pathway, which often falls under general Regulatory Filings (RNS) if a more specific category like 'Capital/Financing Update' (CAP) or 'Legal Proceedings' (LTR) is not applicable. However, because it is a detailed announcement about a clinical trial that directly informs future regulatory submissions, it is best classified as a general Regulatory Filing (RNS) or potentially a general Investor Presentation (IP) if it were structured as slides, but as a press release detailing clinical progress, RNS is the most appropriate fallback for significant, non-standard announcements.
2021-01-18 French
Lettre aux Actionnaires
Report Publication Announcement Classification · 99% confidence The document is titled "Lettre aux Actionnaires" (Letter to Shareholders) and explicitly states that this letter is made available on the company's website under the Investors section. It is a short announcement (2474 characters) informing shareholders about the availability of a specific communication, rather than being the full content of an Annual Report (10-K) or an Interim Report (IR). This structure strongly suggests it is an announcement about the publication of a report or communication intended for investors. Given the options, 'Report Publication Announcement' (RPA) is the most fitting category for a brief notice stating where a shareholder letter can be found. It is not a formal regulatory filing like 10-K or a general regulatory announcement (RNS) unless RPA is unavailable, but RPA specifically covers the announcement of report publication.
2021-01-12 French
Bilan au 31 décembre 2020 du contrat de liquidité contracté avec la Société de Bourse Gilbert Dupont
Transaction in Own Shares Classification · 98% confidence The document is titled "Bilan au 31 décembre 2020 du contrat de liquidité contracté avec la Société de Bourse Gilbert Dupont" (Balance Sheet as of December 31, 2020, for the liquidity contract with Gilbert Dupont Stock Brokerage Firm). It details the status of a liquidity contract, including the number of shares and cash balance held as of the reporting date (Dec 31, 2020), and provides a detailed transaction log (purchases and sales) for the second half of 2020. This type of filing specifically reports on the execution and status of a share buyback/liquidity maintenance program, which aligns directly with the definition of 'Transaction in Own Shares' (POS). It is not a general financial report (10-K, IR) or a simple announcement of a report (RPA).
2021-01-05 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it provides 'Information relative au nombre total de droits de vote et d'actions composant le capital' (Information relative to the total number of voting rights and shares comprising the capital), referencing the French Commercial Code (Article L. 233-8-II) and AMF regulations. This content, detailing the total number of shares and voting rights as of a specific date (07/12/2020), is characteristic of a mandatory disclosure regarding the company's capital structure and voting power. This aligns best with 'Share Issue/Capital Change' (SHA) or potentially a general regulatory filing (RNS). Since it is a specific disclosure about the total number of shares and voting rights, SHA is the most precise fit, as it relates directly to the capital structure, even if it's not a new issuance announcement, but a periodic update on the total count. Given the options, SHA is superior to RNS or MRQ (which is for major *shareholder* changes).
2020-12-17 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.